rosuvastatin 20 mg

1 INDICATIONS AND USAGE Rosuvastatin tablets are indicated: To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to: Reduce LDL-C in adults with primary hyperlipidemia. Reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults. Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: primary dysbetalipoproteinemia. Hypertriglyceridemia. Rosuvastatin tablets are an HMG Co-A reductase inhibitor (statin) indicated: ( 1 ) To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults. As an adjunct to diet to reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: primary dysbetalipoproteinemia. Hypertriglyceridemia.

Rising Health, LLC

FDA Reported Adverse Reactions
`[1] dyspnoea` `[2] drug ineffective` `[3] off label use` `[4] fatigue` `[5] nausea` `[6] headache` `[7] diarrhoea` `[8] pneumonia` `[9] pain` `[10] cough`

5 years ago

ROUND PINK I 31

5 years ago

I 31 ROUND PINK

16 HOW SUPPLIED/STORAGE AND HANDLING Rosuvastatin tablets USP 5 mg are pink, oval shaped, biconvex film-coated tablets debossed with ‘I’ on one side and ‘29’ on the other side. Bottles of 30 NDC 57237-168-30 Bottles of 90 NDC 57237-168-90 Bottles of 500 NDC 57237-168-05 Bottles of 1,000 NDC 57237-168-99 Rosuvastatin tablets USP 10 mg are pink, round, biconvex film-coated tablets debossed with ‘I’ on one side and ‘30’ on the other side. Bottles of 30 NDC 57237-169-30 Bottles of 90 NDC 57237-169-90 Bottles of 500 NDC 57237-169-05 Bottles of 1,000 NDC 57237-169-99 Rosuvastatin tablets USP 20 mg are pink, round, biconvex film-coated tablets debossed with ‘I’ on one side and ‘31’ on the other side. Bottles of 30 NDC 57237-170-30 Bottles of 90 NDC 57237-170-90 Bottles of 500 NDC 57237-170-05 Bottles of 1,000 NDC 57237-170-99 Rosuvastatin tablets USP 40 mg are pink, oval shaped, biconvex film-coated tablets debossed with ‘I’ on one side and ‘32’ on the other side. Bottles of 30 NDC 57237-171-30 Bottles of 90 NDC 57237-171-90 Bottles of 500 NDC 57237-171-05 Bottles of 1,000 NDC 57237-171-99 Storage Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from moisture.

More pills like ROUND I 31